The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...

JPMorgan analyst Daniel Politzer initiated coverage of MGM Resorts (MGM) with a Neutral rating and $38 price target The firm says land-based U.S.

JPMorgan lowered the firm’s price target on Sarepta (SRPT) to $30 from $84 and keeps an Overweight rating on the shares. The firm made changes to ...